The company signed a licensing, production, supply, and commercialization agreement with SteinCares, granting Stein the exclusive commercial rights to the company's BAT2306 (scukinumab) injection in Brazil and the rest of the Americas for compensation. The trade amount consists of a total of up to 8 million USD in upfront and milestone payments, including an upfront payment of 1.2 million USD, cumulative milestone payments not exceeding 6.8 million USD, and a double-digit percentage of net sales as revenue sharing.
百奥泰：与Stein就BAT2306（司库奇尤单抗）注射液签署授权许可及生产、供货和商业化协议
Bio-Thera Solutions: Signed a licensing, production, supply, and commercialization agreement with Stein for BAT2306 (scukinumab) injection.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated